In cancer therapy, their combination with PD‐L1 blockade has shown therapeutic efficacy in mouse models of melanoma and pancreatic cancer by disrupting the immunomodulatory interactions mediated by IL‐6 [411, 412]. This evidence concerns the gene IL6 and cancer.